Special Edition: What's Next—CKD in Type 1 Diabetes—An Urgent Need for Therapies

About this episode

This episode discusses the urgent need for therapies addressing chronic kidney disease in type 1 diabetes with expert insights from Dr. Janet McGill.

There is a fundamental link between diabetes and kidney care. But while there are many medications available to improve CKD outcomes in people with type 2 diabetes, the same options are not available for people with type 1. In this special episode, Dr. Neil Skolnik speaks with Janet McGill, MD, MA, FACE, FACP about the underdiscussed prevalence of CKD in type 1 and the importance of continued development in this area. This special episode is sponsored with support from Bayer . Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts , Amazon Music , Spotify , or your preferred podcast platform. Presented by: Neil Skolnik , MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Janet B. McGill , MD, MA, FACE, FACP, Professor of Medicine at the University of Washington's John T. Milliken Department of Medicine, Division of Endocrinology, Metabolism, and Lipid Research Selected References: Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026…

People in this episode

Host: Neil Skolnik

Guest: Janet McGill

Topics covered

• chronic kidney disease
• type 1 diabetes
• therapies
• diabetes care
• medications
• healthcare

Keywords

• CKD
• type 1 diabetes
• therapies
• kidney care
• medications
• diabetes
• health
• Bayer

Sponsors

Bayer

Mentioned in this episode

Organizations: American Diabetes Association

Books & works: Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026, Finerenone in Type 1 Diabetes and Chronic Kidney Disease, Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

More episodes of DOC Updates

• Special Edition: Hypertension Part 2—Advanced Hypertension Management: Uncontrolled and Resistant Hypertension and the Importance of Aldosterone · September 8, 2026 · 40 min
• Special Edition: Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH) · September 3, 2026 · 23 min
• Special Edition: Evidence-Based Strategies for Weight Loss and Long-Term Weight Maintenance · August 24, 2026 · 32 min
• Special Edition: What's Next—The Role of Health Systems in Managing CKD Associated with T1D & T2D · August 17, 2026 · 33 min
• Katherine Tuttle on SGLT2s & CKD in T2D, Alexander Turchin on medications after Metformin, and High vs. Low CVD Risk, the ADA's statement on employment and diabetes, and more! · August 10, 2026 · 36 min
• Impact of Finerenone on Albuminuria in T1D, National Trends in Out-of-Pocket Cost for Glucose-Lowering Drugs, and more! · August 10, 2026 · 32 min